2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2014 Featured Talks » A novel isoform of the RON kinase transforms pancreatic duct epithelial cells



Part One

Part Two

A novel isoform of the RON kinase transforms pancreatic duct epithelial cells


Andrew Lowy, MD, FACS
Moores Cancer Center




Andrew Lowy, MD, FACS
Chief, Division of Surgical Oncology
Professor of Surgery, UCSD Moores Cancer Center


Andrew M. Lowy, MD is a surgical oncologist with a primary interest and expertise in cancers of the pancreas, liver and GI tract. He has a special interest in the management of patients with metastatic disease to the liver and peritoneum.

Dr. Lowy is recognized worldwide for his expertise in the surgical treatment of pancreatic cancer and for investigating novel cancer treatments which incorporate surgery and chemotherapy to treat patients with advanced cancer that has spread to the abdomen. He has furthered the development of a promising treatment known as the “chemo bath" or heated intraperitoneal chemotherapy (HIPEC), to treat advanced abdominal cancers. During surgery, all visible signs of tumor are removed, and a heated chemotherapy solution is circulated throughout the abdomen for up to 90 minutes. The solution is then removed and the incision closed.

Dr. Lowy serves on the editorial board of the Annals of Surgical Oncology. Dr. Lowy is the co-chair of the National Cancer Institute’s Pancreatic Cancer Task Force which is charged with setting the direction of clinical research in pancreatic cancer in the United States. He also serves as surgical liaison to the Pancreas Committee of the Southwest Oncology Group (SWOG), which is one of the largest National Cancer Institute cooperative groups. He serves as the surgical principal investigator in the largest pancreatic cancer clinical trial ever conducted in the United States. He has conducted extensive research in gastrointestinal and pancreatic cancer and his laboratory holds funding from the National Cancer Institute, The Lustgarten Foundation, AACR/PANCAN, and the National Organization of Rare Diseases.